Drug Trial Radar · NCT06043817
First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations
Last checked: Nov 19, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
345
Planned (sponsor's estimate)
Start
Sep 26, 2023
Primary completion
Dec 1, 2029
Study completion Dec 1, 2029
Sponsor
- Lead sponsor
- Pierre Fabre MedicamentIndustry
- Sponsor type
- Industry
- First posted
- Sep 21, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Study STX-721-101/PFL-721CI101 is an open label, Phase 1/2 study evaluating the safety, tolerability, pharmacokinetic (PK) exposure, and preliminary antitumor activity of STX-721/PFL-721 in participants with non-small cell lung cancer (NSCLC) carrying EGFR or HER2 exon 20 insertion (ex20ins) mutations.
Conditions
- Non-Small Cell Lung Cancer
- NSCLC
- EGFR/HER2 Exon 20 Insertion Mutation
Interventions
STX-721/PFL-721 (Escalated)Drug
STX-721/PFL-721 dose will be escalated per cBLRM-design.
STX-721/PFL-721 (3 dose levels)Drug
Participants will receive STX-721/PFL-721 at one of three dose levels.
STX-721/PFL-721 (RP2D)Drug
Participants will receive the RP2D of STX-721/PFL-721.
STX-721/PFL-721 (Escalated) with platinum-based chemotherapyDrug
STX-721/PFL-721 in combination with platinum-based chemotherapy dose will be escalated per iBOIN-design.
STX-721/PFL-721 with platinum-based chemotherapyDrug
Participants will receive STX-721/PFL-721 at dose selected in Part 1b in combination with platinum-based chemotherapy.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1 Dose Escalation (MTD): Dose Escalation - Number of participants who experience at least 1 DLT during the first 28 days of treatmentTime frame: 28 days
- Part 1 Dose Escalation (OBD): Dose Escalation - Number of participants who experience at least 1 DLT during the first 28 days of treatmentTime frame: 28 days
- Part 2 RP2D Selection: C(max) of STX-721/PFL-721Time frame: 1 year
- Part 2 RP2D Selection: AUC(0-inf) of STX-721/PFL-721Time frame: 1 year
- Part 2 RP2D Selection: AUC(0-t) of STX-721/PFL-721Time frame: 1 year
- Part 2 RP2D Selection: AUC(0-τ) of STX-721/PFL-721Time frame: 1 year
- Part 2 RP2D Selection: Number of participants with confirmed objective response rate (ORR) defined as the percentage of participants with partial response (PR) or complete response (CR) based on RECIST v1.1 per investigator assessment.Time frame: 1 year
- Part 3 Dose Expansion: Number of participants with confirmed ORR defined as the percentage of participants with PR or CR based on RECIST v1.1 per investigator assessment.Time frame: 1 year
Locations
32 sites in 8 countries. Site status is shown where the registry gives one.
City of Hope
Duarte, California · Recruiting
City of Hope
Huntington Beach, California · Recruiting
City of Hope
Irvine, California · Recruiting
Levine Cancer Institute - Charlotte
Charlotte, North Carolina · Recruiting
Thomas Jefferson University Research Facility
Philadelphia, Pennsylvania · Recruiting
SCRI Oncology Partners - PPDS
Nashville, Tennessee · Recruiting
University of Texas MD Anderson Cancer Center
Houston, Texas · Recruiting
University of Utah - Huntsman Cancer Institute - PPDS
Salt Lake City, Utah · Recruiting
NEXT Virginia
Fairfax, Virginia · Recruiting
Chris O'Brien Lifehouse Hospital
Camperdown, New South Wales, Australia · Recruiting
Institut Bergonie - PPDS
Bordeaux, France · Recruiting
CHU de Lille - Hopital Claude Huriez
Lille, France · Recruiting
Centre Léon Bérard
Lyon, France · Recruiting
AP-HM- Hôpital de La Timone
Marseille, France · Recruiting
Institut Claudius Regaud - PPDS
Toulouse, France · Recruiting
Gustave Roussy
Villejuif, France · Recruiting
EDOG Institut de Cancerologie de l'Ouest - PPDS
Saint-Herblain, Loire-Atlantique, France · Recruiting
Charité - Universitätsmedizin Berlin (CBF) - Hindenburgdamm 30
Berlin, Germany · Recruiting
Universitätsklinikum Carl Gustav Carus an der TU Dresden
Dresden, Germany · Recruiting
Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis
Amsterdam, Netherlands · Recruiting
Chungbuk National University Hospital
Cheongju-si, South Korea · Recruiting
National Cancer Center
Goyang-si, South Korea · Recruiting
CHA Bundang Medical Center, CHA University
Seongnam-si, South Korea · Recruiting
Seoul National University Hospital
Seoul, South Korea · Recruiting
Instituto de Investigacion Oncologica Vall dHebron (VHIO) - EPON
Barcelona, Spain · Recruiting
Hospital Universitario Ramon y Cajal
Madrid, Spain · Recruiting
Hospital Universitario 12 de Octubre
Madrid, Spain · Recruiting
Hospital Universitario Virgen del Rocio
Seville, Spain · Recruiting
START - Rioja Hospital Universitario San Pedro
Logroño, La Rioja, Spain · Recruiting
Hospital Regional Universitario de Malaga - Hospital General
Málaga, Malaga, Spain · Recruiting
National Taiwan University Hospital
Taipei, Taiwan · Recruiting
Taipei Veterans General Hospital
Taipei, Taiwan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.